Clinical Trials /

A Study of Nivolumab in Selected Uterine Cancer Patients



The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.

Related Conditions:
  • Carcinosarcoma
  • Endometrial Carcinoma
  • High-Grade Endometrial Stromal Sarcoma
  • Leiomyosarcoma
  • Ovarian Clear Cell Tumor
  • Undifferentiated (Embryonal) Sarcoma
Recruiting Status:



Phase 2

Trial Eligibility



  • Brief Title: A Study of Nivolumab in Selected Uterine Cancer Patients
  • Official Title: Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer

Clinical Trial IDs

  • ORG STUDY ID: 17-180
  • NCT ID: NCT03241745


  • Uterine Cancer
  • Endometrial Carcinoma
  • Carcinosarcoma
  • Leiomyosarcoma
  • Undifferentiated Sarcoma
  • High Grade Endometrial Stromal Sarcoma
  • Clear Cell Carcinoma




The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.

Trial Arms

NivolumabExperimentalNivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
  • Nivolumab

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of metastatic or recurrent uterine cancer
             (endometrial carcinoma, carcinosarcoma, clear cell carcinoma, leiomyosarcoma,
             undifferentiated sarcoma, high grade endometrial stromal sarcoma) by Memorial Sloan
             Kettering Cancer Center. Carcinosarcomas, endometrioid and clear cell carcinomas that
             appears to have arisen in the ovary/fallopian tube or peritoneum are also eligible.
             Recurrence should not be amenable to curative approaches such as surgical resection or

          -  Tumor is confirmed to be one of the following: 1. MSI-high, or 2. MMR-deficient, or 3.
             Hypermutated defined as ≥20 somatic mutations in the tumor by MSK-IMPACT

          -  One or more prior lines of cytotoxic treatment for advanced disease (prior hormonal
             therapy is not considered to count as prior lines of therapy)

          -  Measurable disease by RECIST 1.1 criteria

          -  No known CNS metastases

          -  ECOG Performance status 0-1

          -  ECOG Performance status 0-1

          -  WBC ≥ 2000/uL, ANC ≥ 1500/uL, PLT ≥ 100,000/uL, HGB ≥ 8 g/dL

          -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance of ≥ 40mL/min by Cockroft-Gault

          -  AST (SGOT) and ALT (SGPT) ≤ 3 x ULN

          -  Total bilirubin ≤ 1.5 x ULN, except subjects with Gilbert's syndrome who can have
             total bilirubin ≤ 3.0 mg/dL

          -  Able to sign voluntary written informed consent

          -  Female, 18 years of age or older

          -  Available archival tumor tissue or patient is willing to undergo new biopsy

          -  Premenopausal women of child bearing potential must have a normal urine or serum
             beta-HCG prior to enrollment, and must agree to use effective contraception during
             treatment with nivolumab and for at least 5 months following the last dose of

        Exclusion Criteria:

          -  Disease eligible for potentially curative treatment with standard chemotherapy,
             surgical resection, or chemoradiotherapy.

          -  Known or suspected autoimmune disease, except for subjects with vitiligo, diabetes
             mellitus, resolved childhood asthma/atopy, residual hypothyroidism due to an
             autoimmune immune condition only requiring thyroid hormone replacement, psoriasis not
             requiring systemic treatment, or conditions not expected to recur in the absence of an
             external trigger.

          -  Serious uncontrolled medical disorder or active infection which would impair the
             ability of the subject to receive protocol therapy or whose control would be
             jeopardized by protocol therapy

          -  History of bowel obstruction, refractory ascites, or bowel perforation due to advanced
             disease within the past 3 months from start of study treatment.

          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4
             antibody or any other antibody or drug specifically targeting T cell co-stimulation or
             immune checkpoint pathways

          -  Patients who have a condition that requires systemic treatment with either
             corticosteroids within 7 days of enrollment (systemic corticosteroid therapy is
             defined as >10 mg daily prednisone or its equivalent); or who require other
             immunosuppressive medications within 14 days of study drug administration. Inhaled or
             topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents
             are permitted in the absence of active autoimmune disease.

          -  Prior history of malignancy or a concurrent malignancy, with the exception of
             cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer,
             or in situ carcinoma of the uterine cervix, prostate, or breast, unless a complete
             remission was achieved at least 3 years prior to study entry and no additional therapy
             is required or anticipated to be required during the study period

          -  Breastfeeding women, pregnant women

          -  Prisoners or subjects who are involuntarily incarcerated

          -  Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical illness

               -  Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C
                  virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (if
                  patient has documented Hepatitis B and C from within 6 months of enrollment,
                  these tests do not need to be repeated.)

          -  Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS)

          -  Known allergy or Adverse Drug Reaction to nivolumab, or a history of allergy to study
             drug components.
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression-Free Survival
Time Frame:at 24 weeks
Safety Issue:
Description:will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)


Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Memorial Sloan Kettering Cancer Center

Trial Keywords

  • Nivolumab
  • 17-180

Last Updated

July 21, 2021